The construct will be referred to as CAR.70/IL-15. Non-transduced (NT) NK cells and NK cells transduced with a construct that leads to IL-15 production without a CAR (IL-15 NK cells) were used as controls. We d
NKG2A-KO was performed on iNK cells and CBNK cells in the same methods. iNK cell fratricide assays Mock iNK cells, backbone iNK cells, and CD70-/- iNK cells were stained with CellTrace CFSE (Invitrogen, C34554). And then unstained 70CAR-iNK cells were added as effectors to the co-...
色标显示各标志物的表达水平,红色代表iC9/CAR19/IL-15对照组(CAR)或iC9/CAR19/IL-15CISHKO(CAR KO)NK细胞高表达,蓝色代表低表达(q<0.1,log2倍数变化绝对值>0.8)。(D)GSEA显示与iC9/CAR19/IL-15对照组NK细胞相比,iC9/CAR19/IL-15C...
genetically engineered T cell receptors T (TCR-T) cell therapy, and CAR-T cell therapy [19]. TIL therapy, which involves expanding a heterogeneous population of endogenous T cells with a pool of native TCRs from a harvested tumor, has been approved by the...
expansion and cytotoxic activity of NK cells. It is also used in combination with IL-2 to expand NK cells in vitro10, 11. Sino Biological offers GMP-grade cytokines, includingIL-2,IL-12,IL-15, andIL-21, and also providescomprehensive solutions for CAR-NK therapyto support cellular ...
Adoptive transfer of chimeric antigen receptor (CAR)-modified natural killer (NK) cells represents a transformative approach that has significantly advanced clinical outcomes in patients with malignant hematological conditions. However, the efficacy of C
To date, most adoptive NK cell therapies have utilized PB NK cells, CB NK cells, or NK-92 cells. However, each of these cell sources presents significant limitations, as discussed earlier. Due to the issues of clinical efficacy and donor heterogeneity, considerable attention is now directed tow...
Using natural killer (NK) cells to treat hematopoietic and solid tumors has great promise. Despite their availability from peripheral blood and cord blood, stem cell-derived NK cells provide an “off-the-shelf” solution. In this study, we developed two
ClinicalTrials数据库提供临床试验Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances的登记号NCT05110742,试
Chimeric antigen receptor (CAR) T cell therapy for the treatment of acute myeloid leukemia (AML) has the risk of toxicity to normal myeloid cells. CD7 is expressed by the leukemic blasts and malignant progenitor cells of approximately 30% of AML patients but is absent on normal myeloid and ...